Physician profile
Leah Waller
NPI 1740673250
$17,519.60
in general payments reported to CMS, 2019-2025
28 companies · $976 in 2025
The $976 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,825 · 2022: $7,401 · 2023: $5,835 · 2024: $1,483 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,362 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,891 · Consulting Fee: $1,094 · Travel and Lodging: $792 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,362.27 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,891.00 |
| Consulting Fee | $1,093.50 |
| Travel and Lodging | $792.36 |
| Education | $153.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $7,087.36 | 2021-2025 | Dupixent |
| Genzyme Corporation | $3,497.78 | 2021-2025 | |
| Leo Pharma INC. | $649.73 | 2021-2025 | Adbry, Anzupgo |
| Abbvie INC. | $625.47 | 2022-2025 | |
| Janssen Biotech, INC. | $590.83 | 2021-2024 | Tremfya, Stelara, Remicade |
| Pfizer INC. | $586.60 | 2021-2025 | |
| Incyte Corporation | $583.16 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $548.94 | 2021-2025 | |
| Galderma Laboratories, L.P. | $410.67 | 2021-2023 | Twyneo, Aklief, Oracea |
| E.R. Squibb & Sons, L.L.C. | $346.15 | 2022-2025 | Sotyktu |
| Journey Medical Corporation | $305.27 | 2022-2023 | |
| Lilly USA, LLC | $287.43 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Ucb, INC. | $252.66 | 2021-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $222.93 | 2021-2025 | Winlevi, Absorica Ld |
| Vyne Pharmaceuticals INC. | $219.25 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $217.76 | 2023-2024 | Vtama |
| Revance Therapeutics, INC. | $176.23 | 2024-2025 | Daxxify |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $138.69 | 2021-2025 | Jublia, Arazlo, Cabtreo |
| Lumenis Be INC | $138.41 | 2024 | Optilight |
| Arcutis Biotherapeutics, INC. | $130.12 | 2023-2025 | Zoryve |
| Amgen INC. | $119.54 | 2021-2024 | Otezla |
| Janssen Scientific Affairs, LLC | $100.19 | 2022 | |
| Medimetriks Pharmaceuticals, INC. | $79.27 | 2022-2023 | |
| Strata Skin Sciences, INC. | $66.62 | 2023 | Xtrac |
| Organon LLC | $55.88 | 2025 | Vtama |
| Botanix Sb INC | $33.68 | 2025 | Sofdra |
| Allergan, INC. | $32.74 | 2021 | |
| Nabriva Therapeutics, Plc | $16.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Waller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.